Amr Dessouki, MD
Ophthalmology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location · Retinal Diagnostic Center A Medical Corporation · 6 clinicians in this group
Looking this up.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dessouki’s office at (408) 559-0666 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
Original Medicare doctor bills
$3,021,987
Medicare paid this office $3,021,987 for 1,138 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 252 | $1,862,995 | None |
| Injection, avacincaptad pegol, 0.1 mg | 72 | $375,234 | None |
| Injection of drug into eye | 357 | $160,122 | $104 |
| Established patient complete exam of visual system | 905 | $135,706 | $105 |
| Imaging of retina | 1,064 | $99,691 | $35 |
See all 15 services
| Injection, faricimab-svoa, 0.1 mg | 252 | $1,862,995 | None |
| Injection, avacincaptad pegol, 0.1 mg | 72 | $375,234 | None |
| Injection of drug into eye | 357 | $160,122 | $104 |
| Established patient complete exam of visual system | 905 | $135,706 | $105 |
| Imaging of retina | 1,064 | $99,691 | $35 |
| Injection, ranibizumab, 0.1 mg | 48 | $93,622 | None |
| Established patient problem focused exam of visual system | 483 | $70,126 | $77 |
| Unclassified drugs | 27 | $60,528 | None |
| New patient visit (45+ min) | 234 | $30,426 | $130 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 18 | $20,903 | $1,100 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 119 | $19,752 | $158 |
| Photography of the retina | 321 | $10,800 | $30 |
| Compounded drug, not otherwise classified | 35 | $6,043 | None |
| 2d ultrasound scan of eye tissue and structures | 64 | $3,986 | $44 |
| Photocoagulation treatment to prevent detachment of retina | 15 | $3,695 | $231 |
Who their Medicare patients are
1,138 Original Medicare patients in 2024. Average age 78 · Under 65 3% · 85 and older 22% · Women 58% · Also on Medicaid 13% · Health risk score 1.25. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 73% · Diabetes 31% · Coronary heart disease 25% · Chronic kidney disease 23% · Atrial fibrillation 20% · Cancer 15% · Depression 15% · Heart failure 14% · COPD 10% · Stroke 6% · Dementia 5%.
The office billed $9,906,161, Medicare allowed $3,849,120 and paid $3,021,987; for 80,766 services of 38 kinds; $2,377,909 of it was for drugs given in the office and $644,078 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,138 | 80,766 | 78 | 1.25 | $9,906,161 | $3,021,987 |
| 2023 | 1,229 | 54,968 | 78 | 1.27 | $9,090,767 | $2,553,518 |
| 2022 | 1,102 | 17,217 | 78 | 1.34 | $7,201,142 | $1,975,521 |
| 2021 | 988 | 10,096 | 77 | 1.34 | $5,979,544 | $1,720,155 |
| 2020 | 927 | 9,475 | 77 | 1.40 | $5,376,045 | $1,553,531 |
| 2019 | 1,050 | 10,939 | 77 | 1.44 | $5,594,596 | $1,571,018 |
| 2018 | 1,030 | 11,777 | 76 | 1.47 | $5,299,985 | $1,493,860 |
| 2017 | 988 | 10,521 | 76 | 1.50 | $4,247,574 | $1,113,864 |
| 2016 | 885 | 9,172 | 76 | 1.55 | $4,051,584 | $1,010,725 |
| 2015 | 928 | 9,116 | 76 | 1.50 | $4,017,480 | $1,031,549 |
| 2014 | 895 | 9,053 | 76 | 1.46 | $4,396,477 | $1,248,048 |
| 2013 | 897 | 10,391 | 76 | 1.52 | $4,418,897 | $1,406,498 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Injection, faricimab-svoa, 0.1 mg | 190 | $1,269,024 | None |
| Injection, ranibizumab, 0.1 mg | 168 | $439,895 | None |
| Injection of drug into eye | 400 | $156,609 | $105 |
| Injection, aflibercept, 1 mg | 44 | $146,186 | None |
| Established patient complete exam of visual system | 902 | $136,014 | $102 |
| Established patient problem focused exam of visual system | 477 | $71,954 | $84 |
| Imaging of retina | 695 | $68,775 | $37 |
| Unclassified drugs | 25 | $48,593 | None |
| Photography of the retina | 1,058 | $47,924 | $32 |
| New patient visit (45+ min) | 353 | $47,252 | $134 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 167 | $22,471 | $133 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 20 | $22,060 | $1,103 |
| Compounded drug, not otherwise classified | 54 | $8,465 | None |
| 2d ultrasound scan of eye tissue and structures | 84 | $4,710 | $43 |
| Photocoagulation treatment to prevent detachment of retina | 18 | $4,428 | $233 |
2022: 16 services
| Injection, ranibizumab, 0.1 mg | 184 | $658,391 | None |
| Injection, aflibercept, 1 mg | 90 | $413,669 | None |
| Injection, faricimab-svoa, 0.1 mg | 71 | $184,979 | None |
| Unclassified biologics | 45 | $140,473 | None |
| Injection of drug into eye | 358 | $135,447 | $107 |
| Established patient complete exam of visual system | 804 | $119,303 | $98 |
| Established patient problem focused exam of visual system | 452 | $74,445 | $85 |
| Imaging of retina | 696 | $63,815 | $37 |
| Photography of the retina | 878 | $38,122 | $31 |
| New patient visit (45+ min) | 241 | $32,165 | $133 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 186 | $23,795 | $123 |
| Removal of eye fluid (vitreous) between lens and retina | 14 | $13,812 | $863 |
| Compounded drug, not otherwise classified | 62 | $9,882 | None |
| Destruction of leaking blood vessels of retina using laser | 18 | $7,801 | $312 |
| 2d ultrasound scan of eye tissue and structures | 69 | $4,357 | $45 |
| Return visit (30+ min) | 12 | $942 | $78 |
2021: 15 services
| Injection, ranibizumab, 0.1 mg | 138 | $619,134 | None |
| Injection, aflibercept, 1 mg | 83 | $524,983 | None |
| Established patient complete exam of visual system | 735 | $118,200 | $106 |
| Injection of drug into eye | 293 | $115,377 | $107 |
| Imaging of retina | 787 | $76,362 | $38 |
| Established patient problem focused exam of visual system | 404 | $64,686 | $83 |
| New patient visit (45+ min) | 266 | $36,582 | $138 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 27 | $30,298 | $1,122 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 210 | $25,450 | $114 |
| Photography of the retina | 633 | $24,828 | $32 |
| Photocoagulation treatment to prevent detachment of retina | 26 | $13,690 | $489 |
| Compounded drug, not otherwise classified | 78 | $13,679 | None |
| Destruction of leaking blood vessels of retina using laser | 13 | $7,591 | $316 |
| 2d ultrasound scan of eye tissue and structures | 48 | $3,218 | $46 |
| Injection, bevacizumab, 10 mg | 14 | $972 | None |
2020: 15 services
| Injection, ranibizumab, 0.1 mg | 129 | $605,082 | None |
| Injection, aflibercept, 1 mg | 72 | $426,832 | None |
| Established patient complete exam of visual system | 678 | $107,036 | $104 |
| Injection of drug into eye | 274 | $96,262 | $94 |
| Established patient problem focused exam of visual system | 336 | $54,600 | $82 |
| Photography of the retina | 778 | $49,727 | $40 |
| Imaging of retina | 563 | $46,671 | $37 |
| New patient visit (45+ min) | 230 | $32,545 | $142 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 201 | $21,001 | $101 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 17 | $20,674 | $1,088 |
| Compounded drug, not otherwise classified | 101 | $18,273 | None |
| Photocoagulation treatment to prevent detachment of retina | 24 | $13,108 | $485 |
| Destruction of leaking blood vessels of retina using laser | 15 | $8,061 | $322 |
| 2d ultrasound scan of eye tissue and structures | 39 | $3,253 | $48 |
| Injection, bevacizumab, 10 mg | 12 | $885 | None |
2019: 17 services
| Injection, aflibercept, 1 mg | 88 | $515,447 | None |
| Injection, ranibizumab, 0.1 mg | 76 | $438,296 | None |
| Injection of drug into eye | 308 | $117,183 | $91 |
| Established patient complete exam of visual system | 758 | $115,585 | $105 |
| Established patient problem focused exam of visual system | 522 | $82,483 | $76 |
| Imaging of retina | 751 | $67,658 | $36 |
| Photography of the retina | 794 | $56,935 | $45 |
| New patient visit (45+ min) | 233 | $32,207 | $138 |
| Injection, bevacizumab, 10 mg | 167 | $30,306 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 268 | $25,633 | $86 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 15 | $18,953 | $1,115 |
| Photocoagulation treatment to prevent detachment of retina | 18 | $11,127 | $484 |
| Destruction of leaking blood vessels of retina using laser | 23 | $10,289 | $303 |
| Compounded drug, not otherwise classified | 65 | $5,528 | None |
| Examination of eye by ophthalmoscope with retinal drawing | 91 | $4,230 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 88 | $4,220 | $25 |
| 2d ultrasound scan of eye tissue and structures | 43 | $2,895 | $56 |
2018: 16 services
| Injection, ranibizumab, 0.1 mg | 78 | $477,158 | None |
| Injection, aflibercept, 1 mg | 80 | $376,738 | None |
| Injection of drug into eye | 311 | $123,505 | $88 |
| Established patient complete exam of visual system | 733 | $108,247 | $99 |
| Established patient problem focused exam of visual system | 469 | $86,121 | $76 |
| Imaging of retina | 803 | $79,535 | $35 |
| Injection, bevacizumab, 10 mg | 220 | $44,387 | None |
| Photography of the retina | 634 | $44,329 | $51 |
| New patient visit (45+ min) | 289 | $38,394 | $133 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 253 | $21,476 | $79 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 15 | $17,510 | $1,094 |
| Photocoagulation treatment to prevent detachment of retina | 20 | $9,739 | $464 |
| Examination of eye by ophthalmoscope with retinal drawing | 179 | $8,988 | $22 |
| 2d ultrasound scan of eye tissue and structures | 61 | $6,209 | $67 |
| Examination of eye by ophthalmoscope with retinal drawing | 92 | $4,201 | $24 |
| Exam of visual field with extended testing | 20 | $1,180 | $56 |
2017: 17 services
| Injection, aflibercept, 1 mg | 62 | $361,836 | None |
| Injection, ranibizumab, 0.1 mg | 44 | $157,207 | None |
| Established patient complete exam of visual system | 699 | $109,078 | $99 |
| Injection of drug into eye | 292 | $98,806 | $87 |
| Imaging of retina | 798 | $79,337 | $35 |
| Established patient problem focused exam of visual system | 457 | $70,899 | $73 |
| Injection, bevacizumab, 10 mg | 225 | $42,439 | None |
| New patient visit (45+ min) | 286 | $36,955 | $129 |
| Photography of the retina | 454 | $31,241 | $59 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 321 | $24,233 | $70 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 15 | $16,197 | $1,080 |
| Examination of eye by ophthalmoscope with retinal drawing | 207 | $9,598 | $21 |
| Destruction of growth of retina using a laser | 14 | $8,827 | $441 |
| Photocoagulation treatment to prevent detachment of retina | 18 | $8,727 | $459 |
| Examination of eye by ophthalmoscope with retinal drawing | 163 | $7,259 | $23 |
| 2d ultrasound scan of eye tissue and structures | 49 | $5,957 | $82 |
| Destruction of leaking blood vessels of retina using laser | 13 | $4,726 | $295 |
2016: 20 services
| Injection, aflibercept, 1 mg | 61 | $367,399 | None |
| Injection of drug into eye | 271 | $100,723 | $87 |
| Established patient complete exam of visual system | 628 | $87,615 | $96 |
| Imaging of retina | 725 | $81,316 | $38 |
| Established patient problem focused exam of visual system | 405 | $63,469 | $72 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 278 | $56,230 | $93 |
| Injection, bevacizumab, 10 mg | 223 | $48,921 | None |
| Injection, ranibizumab, 0.1 mg | 14 | $38,196 | None |
| New patient visit (45+ min) | 254 | $32,999 | $130 |
| Photography of the retina | 363 | $26,489 | $64 |
| Removal of membrane of retina | 12 | $14,085 | $1,083 |
| Destruction of leaking blood vessels of retina using laser | 20 | $11,700 | $285 |
| Removal of eye fluid (vitreous) between lens and retina | 11 | $10,121 | $843 |
| Destruction of growth of retina using a laser | 15 | $9,728 | $442 |
| Photocoagulation treatment to prevent detachment of retina | 19 | $9,277 | $442 |
| Examination of eye by ophthalmoscope with retinal drawing | 149 | $6,927 | $23 |
| 2d ultrasound scan of eye tissue and structures | 53 | $6,212 | $82 |
| Examination of eye by ophthalmoscope with retinal drawing | 135 | $5,888 | $21 |
| Injection of drug or substance into membrane covering eyeball | 11 | $1,344 | $84 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $89 | None |
2015: 19 services
| Injection, aflibercept, 1 mg | 55 | $388,967 | None |
| Established patient complete exam of visual system | 634 | $97,101 | $94 |
| Injection of drug into eye | 265 | $86,686 | $85 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 367 | $78,769 | $93 |
| Imaging of retina | 715 | $72,194 | $38 |
| Established patient problem focused exam of visual system | 347 | $48,440 | $76 |
| Injection, bevacizumab, 10 mg | 223 | $39,922 | None |
| Photography of the retina | 457 | $33,052 | $63 |
| New patient complete exam of visual system | 191 | $21,607 | $113 |
| Destruction of leaking blood vessels of retina using laser | 17 | $21,058 | $842 |
| Examination of eye by ophthalmoscope with retinal drawing | 332 | $15,600 | $23 |
| New patient visit (45+ min) | 111 | $15,390 | $139 |
| Removal of membrane of retina | 14 | $15,040 | $1,074 |
| Destruction of growth of retina using a laser | 22 | $13,579 | $411 |
| Photocoagulation treatment to prevent detachment of retina | 20 | $9,064 | $432 |
| 2d ultrasound scan of eye tissue and structures | 49 | $6,473 | $81 |
| Examination of eye by ophthalmoscope with retinal drawing | 81 | $3,663 | $21 |
| Exam of visual field with extended testing | 16 | $983 | $58 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $67 | None |
2014: 19 services
| Injection, aflibercept, 1 mg | 45 | $364,956 | None |
| Injection, ranibizumab, 0.1 mg | 56 | $223,076 | None |
| Established patient complete exam of visual system | 702 | $153,863 | $99 |
| Injection of drug into eye | 239 | $93,410 | $91 |
| Imaging of retina | 695 | $80,128 | $41 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 360 | $73,795 | $95 |
| Destruction of leaking blood vessels of retina using laser | 26 | $31,443 | $898 |
| Injection, bevacizumab, 10 mg | 183 | $30,202 | None |
| Photography of the retina | 414 | $30,089 | $66 |
| Established patient problem focused exam of visual system | 151 | $21,325 | $75 |
| Destruction of growth of retina using a laser | 31 | $19,214 | $457 |
| New patient visit (45+ min) | 154 | $18,937 | $123 |
| Removal of membrane of retina | 11 | $13,647 | $1,241 |
| New patient complete exam of visual system | 107 | $13,641 | $127 |
| Photocoagulation treatment to prevent detachment of retina | 20 | $10,448 | $475 |
| Examination of eye by ophthalmoscope with retinal drawing | 175 | $8,990 | $24 |
| 2d ultrasound scan of eye tissue and structures | 50 | $6,067 | $84 |
| Injection of drug or substance into membrane covering eyeball | 13 | $1,219 | $87 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $49 | None |
2013: 25 services
| Injection, ranibizumab, 0.1 mg | 86 | $587,604 | None |
| Established patient complete exam of visual system | 733 | $178,210 | $103 |
| Injection, aflibercept, 1 mg | 32 | $123,817 | None |
| Injection of drug into eye | 242 | $80,864 | $90 |
| Imaging of retina | 659 | $71,993 | $41 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 330 | $69,079 | $98 |
| Destruction of leaking blood vessels of retina using laser | 24 | $41,029 | $912 |
| Photography of the retina | 433 | $31,184 | $65 |
| New patient visit (45+ min) | 224 | $29,039 | $130 |
| Established patient problem focused exam of visual system | 157 | $24,898 | $68 |
| Unclassified biologics | 106 | $19,892 | None |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 13 | $17,498 | $1,346 |
| Destruction of growth of retina using a laser | 31 | $16,400 | $469 |
| Removal of membrane of retina | 12 | $14,296 | $1,191 |
| Injection, bevacizumab, 10 mg | 91 | $9,830 | None |
| Photocoagulation treatment to prevent detachment of retina | 18 | $8,095 | $450 |
| 2d ultrasound scan of eye tissue and structures | 63 | $7,529 | $85 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 18 | $4,698 | $204 |
| Removal of eye fluid | 16 | $1,942 | $97 |
| Extended office or other outpatient service, first hour | 19 | $1,606 | $85 |
| Injection of drug or substance into membrane covering eyeball | 16 | $1,518 | $84 |
| Long return visit (40+ min) | 15 | $1,381 | $92 |
| Exam of visual field with extended testing | 14 | $1,260 | $57 |
| New patient visit (30+ min) | 13 | $845 | $65 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $19 | None |
Medicaid work
$83,959 in 2024
Medicaid paid $83,959 for 1,375 billed services this clinician did in 2024, up to 64 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Injection, faricimab-svoa, 0.1 mg | 95 | $50,431 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 290 | $14,162 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 476 | $5,401 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 171 | $4,152 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 132 | $3,936 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 126 | $2,146 |
| Injection, bevacizumab, 10 mg | 55 | $1,989 |
| Return visit (30+ min) | 17 | $1,272 |
| New patient visit (45+ min) | 13 | $470 |
| 2024 | 1,375 | 9 | 64 | $83,959 |
| 2023 | 1,617 | 10 | 57 | $62,514 |
| 2022 | 1,918 | 8 | 54 | $69,644 |
| 2021 | 1,759 | 8 | 72 | $63,925 |
| 2020 | 1,496 | 8 | 40 | $51,637 |
| 2019 | 1,960 | 8 | 57 | $70,758 |
| 2018 | 2,137 | 14 | 66 | $72,120 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 334 | $17,497 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 241 | $10,166 |
| Ranibizumab injection | 26 | $7,098 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 371 | $7,013 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 154 | $5,330 |
| Injection, faricimab-svoa, 0.1 mg | 13 | $5,252 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 393 | $5,063 |
| New patient visit (45+ min) | 56 | $3,401 |
| Return visit (30+ min) | 13 | $900 |
| Injection, bevacizumab, 10 mg | 16 | $795 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 375 | $21,481 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 331 | $13,519 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 245 | $8,234 |
| Ranibizumab injection | 27 | $8,046 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 375 | $7,165 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 460 | $6,331 |
| New patient visit (45+ min) | 46 | $2,481 |
| Injection, bevacizumab, 10 mg | 59 | $2,388 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 315 | $25,774 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 325 | $11,374 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 213 | $7,245 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 531 | $7,101 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 266 | $5,117 |
| New patient visit (45+ min) | 48 | $3,076 |
| Injection, bevacizumab, 10 mg | 49 | $2,190 |
| Ranibizumab injection | 12 | $2,049 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 317 | $18,592 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 314 | $8,168 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 270 | $8,091 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 364 | $5,956 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 137 | $5,578 |
| Injection, bevacizumab, 10 mg | 43 | $2,159 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 36 | $2,061 |
| New patient visit (45+ min) | 15 | $1,032 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 376 | $29,473 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 261 | $10,597 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 494 | $7,553 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 298 | $6,961 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 293 | $6,943 |
| Injection, bevacizumab, 10 mg | 168 | $6,034 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 57 | $2,259 |
| New patient visit (45+ min) | 13 | $938 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 352 | $31,425 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 267 | $9,133 |
| Injection, bevacizumab, 10 mg | 264 | $7,966 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 530 | $7,728 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 253 | $7,580 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 192 | $4,035 |
| New patient visit (45+ min) | 38 | $2,668 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 29 | $1,586 |
| TOBACCO NON-USER | 46 | $0 |
| Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM) | 41 | $0 |
| 7 standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM) | 40 | $0 |
| Eye imaging validated to match diagnosis from 7 standard field stereoscopic retinal photos results documented and reviewed; with evidence of retinopathy (DM) | 40 | $0 |
Drugs they prescribed that Part D paid
$12,494
Pharmacies billed $12,494 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 160) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
90 generic and 70 brand-name prescriptions · $12,494 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lumigan | 13 | $7,375 | $567 |
| Tobramycin-Dexamethasone | 56 | $2,160 | $39 |
| Prednisolone Acetate | 33 | $1,822 | $55 |
| Diclofenac | 24 | $257 | $11 |
| Latanoprost | 12 | $81 | $7 |
Year by year
| 2024 | 160 | 81 | 0% (0) | 44% | $12,494 |
| 2023 | 180 | 99 | 0% (0) | 46% | $18,438 |
| 2022 | 187 | 94 | 0% (0) | 42% | $15,882 |
| 2021 | 152 | 89 | None | 58% | $12,175 |
| 2020 | 110 | 69 | 0% (0) | 47% | $8,401 |
| 2019 | 124 | 63 | 0% (0) | 55% | $9,537 |
| 2018 | 123 | 65 | None | 49% | $6,798 |
| 2017 | 179 | 73 | None | 59% | $16,106 |
| 2016 | 190 | 78 | 0% (0) | 66% | $18,053 |
| 2015 | 223 | 82 | None | 73% | $22,849 |
| 2014 | 235 | 68 | 0% (0) | 74% | $26,934 |
| 2013 | 340 | 98 | None | 71% | $32,062 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Lumigan | 14 | $7,201 | $514 |
| Tobramycin-Dexamethasone | 56 | $3,688 | $66 |
| Prednisolone Acetate | 37 | $2,389 | $65 |
| Brimonidine | 16 | $620 | $39 |
| Diclofenac | 15 | $183 | $12 |
| Latanoprost | 12 | $134 | $11 |
2022: 5 drugs
| Tobramycin-Dexamethasone | 50 | $3,889 | $78 |
| Brimonidine | 32 | $1,977 | $62 |
| Prednisolone Acetate | 31 | $1,885 | $61 |
| Diclofenac | 18 | $230 | $13 |
| Latanoprost | 13 | $105 | $8 |
2021: 4 drugs
| Tobramycin-Dexamethasone | 65 | $5,569 | $86 |
| Prednisolone Acetate | 24 | $1,807 | $75 |
| Brimonidine | 14 | $1,433 | $102 |
| Latanoprost | 24 | $217 | $9 |
2020: 2 drugs
| Tobramycin-Dexamethasone | 45 | $3,927 | $87 |
| Prednisolone Acetate | 18 | $1,296 | $72 |
2019: 2 drugs
| Tobramycin-Dexamethasone | 31 | $2,621 | $85 |
| Prednisolone Acetate | 24 | $1,327 | $55 |
2018: 2 drugs
| Tobramycin-Dexamethasone | 43 | $3,337 | $78 |
| Prednisolone Acetate | 29 | $1,819 | $63 |
2017: 5 drugs
| Tobramycin-Dexamethasone | 49 | $4,946 | $101 |
| Travatan Z | 15 | $3,409 | $227 |
| Prednisolone Acetate | 39 | $1,961 | $50 |
| Brimonidine | 11 | $1,574 | $143 |
| Latanoprost | 19 | $223 | $12 |
2016: 6 drugs
| Tobramycin-Dexamethasone | 45 | $5,992 | $133 |
| Brimonidine | 19 | $2,359 | $124 |
| Prednisolone Acetate | 39 | $2,210 | $57 |
| Alphagan P | 11 | $1,894 | $172 |
| Atropine Sulfate | 11 | $315 | $29 |
| Timolol Maleate | 11 | $58 | $5 |
2015: 5 drugs
| Tobramycin-Dexamethasone | 35 | $4,802 | $137 |
| Nevanac | 21 | $4,473 | $213 |
| Brimonidine | 33 | $3,449 | $105 |
| Prednisolone Acetate | 57 | $3,403 | $60 |
| Timolol Maleate | 14 | $125 | $9 |
2014: 6 drugs
| Nevanac | 31 | $5,337 | $172 |
| Tobramycin-Dexamethasone | 33 | $5,160 | $156 |
| Brimonidine | 36 | $3,653 | $101 |
| Lumigan | 22 | $3,596 | $163 |
| Prednisolone Acetate | 45 | $2,513 | $56 |
| Timolol Maleate | 14 | $87 | $6 |
2013: 7 drugs
| Tobramycin-Dexamethasone | 55 | $9,381 | $171 |
| Brimonidine | 50 | $4,439 | $89 |
| Nevanac | 23 | $3,411 | $148 |
| Travatan Z | 20 | $2,882 | $144 |
| Prednisolone Acetate | 69 | $1,816 | $26 |
| Atropine Sulfate | 14 | $241 | $17 |
| Timolol Maleate | 11 | $75 | $7 |
Money from drug and device companies
$3,405 in 2025
| 2025 | 10 | 31 | None | $3,405 |
| 2024 | 9 | 38 | None | $3,004 |
| 2023 | 9 | 29 | None | $1,058 |
| 2022 | 5 | 14 | None | $671 |
| 2021 | 2 | 5 | None | $111 |
| 2020 | 4 | 10 | None | $221 |
| 2019 | 4 | 19 | None | $704 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | Syfovre | $2,396 | 7 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $281 | 2 payments
|
| Astellas Pharma US | Izervay | $224 | 9 payments
|
| Genentech USA | Vabysmo | $185 | 6 payments
|
| Alcon Vision | Hydrus Microstent | $159 | 1 payment
|
| Amgen | Tepezza | $51 | 2 payments
|
See all 31 published payments
| Astellas Pharma US | Meals · 2025-12-18 | Izervay | $15 |
| Regeneron Pharmaceuticals | Meals · 2025-12-04 | Eylea Hd | $131 |
| Astellas Pharma US | Meals · 2025-11-24 | Izervay | $3 |
| Apellis Pharmaceuticals | Meals · 2025-11-13 | Syfovre | $10 |
| Apellis Pharmaceuticals | Meals · 2025-11-13 | Syfovre | $8 |
| Apellis Pharmaceuticals | Meals · 2025-11-12 | None | $100 |
| Apellis Pharmaceuticals | Travel · 2025-11-12 | None | $246 |
| Apellis Pharmaceuticals | Travel · 2025-11-12 | None | $1,987 |
| Apellis Pharmaceuticals | Meals · 2025-11-11 | Syfovre | $10 |
| Mallinckrodt Hospital Products | Meals · 2025-11-04 | Acthar | $36 |
| Genentech USA | Meals · 2025-10-24 | Vabysmo | $27 |
| Genentech USA | Meals · 2025-10-14 | Vabysmo | $35 |
| Amgen | Meals · 2025-10-10 | Tepezza | $25 |
| Genentech USA | Meals · 2025-09-26 | Vabysmo | $35 |
| Astellas Pharma US | Meals · 2025-09-15 | Izervay | $23 |
| Astellas Pharma US | Meals · 2025-07-09 | Izervay | $28 |
| Genentech USA | Meals · 2025-06-25 | Vabysmo | $30 |
| Alcon Vision | Meals · 2025-06-17 | Hydrus Microstent | $159 |
| Regeneron Healthcare Solutions | Meals · 2025-06-13 | Eylea Hd | $23 |
| Amgen | Meals · 2025-06-06 | Tepezza | $26 |
| ANI Pharmaceuticals | Meals · 2025-06-03 | Yutiq | $28 |
| Apellis Pharmaceuticals | Meals · 2025-05-28 | Syfovre | $34 |
| Astellas Pharma Global Development | Meals · 2025-05-14 | Izervay | $23 |
| Regeneron Pharmaceuticals | Meals · 2025-04-16 | None | $150 |
| Genentech USA | Meals · 2025-03-26 | Vabysmo | $29 |
| Astellas Pharma US | Meals · 2025-03-14 | Izervay | $35 |
| Astellas Pharma US | Meals · 2025-02-27 | Izervay | $25 |
| Genentech USA | Meals · 2025-02-21 | Vabysmo | $29 |
| Astellas Pharma US | Meals · 2025-02-05 | Izervay | $33 |
| Astellas Pharma US | Meals · 2025-01-22 | Izervay | $35 |
| Astellas Pharma US | Meals · 2025-01-08 | Izervay | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,004
| EyePoint Pharmaceuticals US | Eyp-1901 | $1,674 | 5 payments
|
| Astellas Pharma US | Izervay | $654 | 16 payments
|
| Genentech USA | Vabysmo | $209 | 7 payments
|
| Mallinckrodt Hospital Products | Acthar | $140 | 1 payment
|
| Abbvie | Ozurdex | $107 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $88 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $64 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $45 | 2 payments
|
| Harrow Eye | Iheezo | $23 | 1 payment
|
2023: $1,058
| Apellis Pharmaceuticals | Syfovre | $266 | 6 payments
|
| Genentech USA | Vabysmo | $243 | 8 payments
|
| Astellas Pharma US | None | $219 | 6 payments
|
| Biogen | None | $126 | 2 payments
|
| Bausch & Lomb Americas | Xipere | $59 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $55 | 2 payments
|
| AbbVie | Ozurdex | $53 | 2 payments
|
| Harrow Eye | Iheezo | $20 | 1 payment
|
| Coherus Biosciences | Cimerli | $18 | 1 payment
|
2022: $671
| Genentech USA | Vabysmo | $329 | 8 payments
|
| Apellis Pharmaceuticals | None | $185 | 3 payments
|
| Regeneron Pharmaceuticals | Eylea | $112 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $23 | 1 payment
|
| EyePoint Pharmaceuticals US | Yutiq | $22 | 1 payment
|
2021: $111
| Genentech USA | Lucentis | $96 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $15 | 1 payment
|
2020: $221
| Genentech USA | Lucentis | $144 | 6 payments
|
| Optos | P200dtx | $39 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $20 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Visudyne | $18 | 1 payment
|
2019: $704
| Novartis Pharmaceuticals | Beovu | $461 | 12 payments
|
| Genentech USA | Lucentis | $185 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $39 | 2 payments
|
| Optos | P200dtx | $20 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2022 | Their institution | $197,940 |
| Genentech, Inc. · Va2 Phiii · 2020 | Their institution | $171,175 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2021 | Their institution | $148,175 |
| Genentech, Inc. · Va2 Phiii · 2021 | Their institution | $131,533 |
| NOVARTIS PHARMACEUTICALS CORPORATION · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2020 | Their institution | $105,196 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2023 | Their institution | $86,214 |
| Genentech, Inc. · Faricimab for Under Represented Patients With Dme · 2025 | Their institution | $76,444 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2022 | Their institution | $74,818 |
| Genentech, Inc. · Faricimab for Under Represented Patients With Dme · 2024 | Their institution | $63,881 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2020 | Their institution | $56,158 |
| Genentech, Inc. · Va2 Phiii · 2019 | Their institution | $55,941 |
| Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2022 | Their institution | $55,752 |
| Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2023 | Their institution | $48,754 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2025 | Their institution | $47,685 |
| Genentech, Inc. · Ah and Imaging Biomarker Study · 2022 | Their institution | $43,783 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2023 | Their institution | $41,737 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2021 | Their institution | $38,906 |
| Genentech, Inc. · Va2 Phiii Yosemite · 2019 | Their institution | $35,232 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2021 | Their institution | $27,805 |
| Genentech, Inc. · Faricimab for Under Represented Patients With Dme · 2023 | Their institution | $26,279 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2023 | Their institution | $24,504 |
| Hexal AG · Csok583a12301 · 2022 | Their institution | $21,449 |
| Genentech, Inc. · Faricimab for Under Represented Patients With Dme · 2022 | Their institution | $21,134 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2022 | Their institution | $20,475 |
| Astellas Pharma Global Development · An Open-Label Extension (Ole) Phase 3 Trial To Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study Isee2008 (Gather2) · 2023 | Their institution | $20,288 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2021 | Their institution | $20,248 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2019 | Their institution | $19,630 |
| TOPCON CORPORATION · Protocol Tpc2020-001 Oct Technology and Software Evaluation · 2020 | Their institution | $16,844 |
| Astellas Pharma Global Development · A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial To Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atropy Secondary To Age-Related Macular Degeneration · 2023 | Their institution | $16,564 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2024 | Their institution | $16,420 |
| Hexal AG · Csok583a12301 · 2021 | Their institution | $15,244 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2022 | Their institution | $15,047 |
| Boehringer Ingelheim International GmbH · Bi 764524 Phase 2b · 2024 | Their institution | $14,589 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2023 | Their institution | $14,578 |
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran Or Cemdisiran Alone in Participants With Geographic Atrophy Secondary To Age-Related Macular Degeneration · 2025 | Their institution | $14,200 |
| ABBVIE INC. · Study To Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (Namd) · 2025 | Their institution | $14,000 |
| Genentech, Inc. · A Phase 1 Sad MD in Diabetic Macular Edema · 2025 | Their institution | $14,000 |
| Genentech, Inc. · Constance Faricimab in Namd Patients · 2025 | Their institution | $13,500 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 Mg Aflibercept in Participants With Macular Edema Following Retinal Vein Occlusion · 2025 | Their institution | $13,500 |
| EyePoint Pharmaceuticals US, Inc. · A 2-Year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Aflibercept in Subjects With Wet Amd · 2024 | Their institution | $12,500 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2024 | Their institution | $11,952 |
| Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2021 | Their institution | $11,815 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2021 | Their institution | $11,613 |
| Genentech, Inc. · Va2 Phiii · 2022 | Their institution | $11,058 |
| EyePoint Pharmaceuticals US, Inc. · A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Aflibercept in Subjects With Wet Amd · 2023 | Their institution | $9,450 |
| Apellis Pharmaceuticals, Inc. · A Study To Compare the Efficacy and Safety of Intravitreal Apl-2 Therapy With Sham Injections in Patients With Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration · 2022 | Their institution | $8,434 |
| Novartis Pharmaceuticals Corporation · A First-in-Human, Open-Label, Single Ascending Dose Study To Assess Safety and Tolerability of Intravitreal Mhu650 in Patients With Macular Edema · 2021 | Their institution | $7,500 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Branch Retinal Vein Occlusion · 2021 | Their institution | $7,500 |
| Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2024 | Their institution | $7,267 |
| Genentech, Inc. · Ph III Study To Evaluate the Efficacy and Safety of Astegolimab in Copd · 2025 | Their institution | $7,266 |
| EyePoint Pharmaceuticals US, Inc. · A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Aflibercept in Subjects With Wet Amd · 2024 | Their institution | $6,809 |
| Allergan Inc. · A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-Related Macular Degeneration · 2019 | Their institution | $6,095 |
| Boehringer Ingelheim International GmbH · Crimson: A Multicentre, Randomised, Sham-Controlled (and Active Controlled in the USA), Double-Masked, 72-Week Trial To Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal Bi 764524 in Patients With Moderately Severe To Severe Non-Proliferative Diabetic Retinopathy · 2025 | Their institution | $6,069 |
| Genentech, Inc. · Ah and Imaging Biomarker Study · 2021 | Their institution | $5,858 |
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran Or Cemdisiran Alone in Participants With Geographic Atrophy Secondary To Age-Related Macular Degeneration · 2025 | This clinician | $5,298 |
| Novartis Pharmaceuticals Corporation · A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 Mg Compared To Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy · 2020 | Their institution | $5,007 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2025 | Their institution | $4,400 |
| Hexal AG · Csok583a12301 · 2023 | Their institution | $3,888 |
| Astellas Pharma Global Development · A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial To Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atropy Secondary To Age-Related Macular Degeneration · 2024 | Their institution | $3,000 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Branch Retinal Vein Occlusion · 2023 | Their institution | $2,249 |
| Apellis Pharmaceuticals, Inc. · Gale · 2021 | Their institution | $1,215 |
| ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy · 2025 | Their institution | $714 |
| Novartis Pharmaceuticals Corporation · A First-in-Human, Open-Label, Single Ascending Dose Study To Assess Safety and Tolerability of Intravitreal Mhu650 in Patients With Macular Edema · 2022 | Their institution | $189 |
| Novartis Pharmaceuticals Corporation · A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 Mg Compared To Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy · 2021 | Their institution | $148 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013905389
- Licence
- CA 453889
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A538890
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 3395 S Bascom Ave Ste 140, Campbell, CA, 95008
- NPI first listed
- 2005-10-11
- NPI last updated
- 2025-11-18
- NPI record certified
- 2025-11-18
This is when the NPI record was last certified, not a medical board exam.